ArticleScientific reports2026
Integrated molecular, microRNA, and biochemical profiling reveals oxidative stress-driven degeneration of the ligamentum flavum in lumbar spinal stenosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative lumbar spinal stenosis (LSS) is driven by fibrosis and hypertrophy of the ligamentum flavum (LF). Oxidative stress-an excess of reactive oxygen species (ROS) over antioxidant defenses-may underlie LF remodeling, but tissue-level evidence is limited. LF from patients with LSS (n = 180) and controls (n = 102) underwent transcriptomic microarray and microRNA (miRNA) profiling, reverse-transcription quantitative PCR (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and biochemical assays of thiobarbituric acid-reactive substances (TBARS), total glutathione (GSH), and glutathione peroxidase (GPx) activity. Protein-protein interaction (PPI) and functional enrichment analyses were performed. Among 14,130 oxidative-stress-related transcripts, 8,197 were differentially expressed (p < 0.05). Redox-sensitive inflammatory mediators were upregulated, including tumor necrosis factor (TNF), interleukin-1β (IL-1B), interleukin-6 (IL-6), and C-X-C motif chemokine ligand 8 (CXCL8), alongside mitogen-activated protein kinases (MAPK8/JNK1, MAPK14/p38α, MAPK1/ERK2) and superoxide dismutase 2 (SOD2) and peroxiredoxin-1 (PRDX1). Antioxidant defenses-catalase (CAT), superoxide dismutases SOD1/SOD3, glutathione peroxidase-1 (GPX1), and sirtuin-3 (SIRT3)-were downregulated. RT-qPCR confirmed these trends. ELISA demonstrated higher MAPK8 and IL-6 and lower SIRT3 and GPX1 in hypertrophic LF (all p < 0.05). Biochemically, LSS tissue showed increased TBARS and GPx activity and decreased GSH versus controls; oxidative imbalance intensified with greater pain and higher body mass index. Selected miRNAs (e.g., hsa-miR-3163→MAPK8, hsa-miR-4291→SIRT3) were reduced. PPI networks were highly enriched (p < 1 × 10⁻¹⁶). Notably, MAPK8, SIRT3, GPX1, and IL-6 dysregulation was independent of pain category. LF in LSS exhibits a persistent ROS-driven, MAPK-amplified inflammatory program with mitochondrial vulnerability (SIRT3 loss) and impaired peroxide detoxification (GPX1 decline). This oxidative signature likely sustains fibrosis and LF thickening and nominates MAPK8-SIRT3-GPX1-IL-6 as candidate biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.